| Literature DB >> 30619842 |
Sena Yaman1, Muge Anil-Inevi1, Engin Ozcivici1, H Cumhur Tekin1.
Abstract
Live cell manipulation is an important biotechnological tool for cellular and tissue level bioengineering applications due to its capacity for guiding cells for separation, isolation, concentration, and patterning. Magnetic force-based cell manipulation methods offer several advantages, such as low adverse effects on cell viability and low interference with the cellular environment. Furthermore, magnetic-based operations can be readily combined with microfluidic principles by precisely allowing control over the spatiotemporal distribution of physical and chemical factors for cell manipulation. In this review, we present recent applications of magnetic force-based cell manipulation in cellular and tissue bioengineering with an emphasis on applications with microfluidic components. Following an introduction of the theoretical background of magnetic manipulation, components of magnetic force-based cell manipulation systems are described. Thereafter, different applications, including separation of certain cell fractions, enrichment of rare cells, and guidance of cells into specific macro- or micro-arrangements to mimic natural cell organization and function, are explained. Finally, we discuss the current challenges and limitations of magnetic cell manipulation technologies in microfluidic devices with an outlook on future developments in the field.Entities:
Keywords: cell culture; magnetic manipulations; microfluidics; rare cell separation; tissue engineering
Year: 2018 PMID: 30619842 PMCID: PMC6305723 DOI: 10.3389/fbioe.2018.00192
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1Schematic illustration of microfluidic-based rare cell isolation methods. (I) Target cells labeled with MNPs, (II) Unwanted cells labeled with MNPs, (III) In situ magnetic labeling of target cells, (IV) MNP internalization, and (V) Label-free magnetic separation based on cells' intrinsic properties.
Microfluidic rare cell separation applications based on positive and negative magnetophoresis.
| Endothelial progenitor cells (EPCs) | PM -MNP internalization (positive enrichment) | NU | NdFeB permanent magnet | NR | NR | 40% | 0.3 mL h−1 | No difference between treated and untreated cells after 24 h in viability and tube formation function was reported | Kim et al., |
| Hematopoietic stem cells (HSCs) | PM -MNP labeling | CD34 | Permanent magnet | NR | 5 × 107 cells mL−1 | 88% | 0.15 mL h−1 | NR | Wu et al., |
| Hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs) | PM | CD133 | Electromagnetic wire | NR | HSC: ~6750 cells mL−1 EPC: ~1190 cells mL−1 | HSC: > 96% | >14 mL h−1 | No adverse effect on cell viability | Plouffe et al., |
| Mouse lung multipotent stem cells (MLSCs) | PM | CD45 (-) | Magnet | 96–99% | NR | NR | 1.2 mL h−1 | Good self-renewal and proliferation capacity was obtained | Zeng et al., |
| Human colon adenocarcinoma cells (COLO205) and human breast cancer cells | PM | EpCAM | NdFeB permanent magnet | NR | 5–1,000 cells mL−1 | COLO205: 90% | 10 mL h−1 | NR | Hoshino et al., |
| Mouse metastatic breast cancer cells (M6C) | PM | EpCAM | NdFeB permanent magnet | <0.4% WBC capture | 2–80 cells mL−1 | ~90% | 1.2 mL h−1 | > 90% | Kang et al., |
| Breast cancer cells (MCF-7) and lung cancer cells | PM | EpCAM | Permanent magnet | NR | ~10 cells mL−1 | ~80% | NR | NR | Yoo et al., |
| Human breast cancer cells (MCF-7 and MDA-MB-23) | PM | EpCAM | Permanent magnet | NR | 103- 105 cells mL−1 | MCF-7: 95.7% | 3 mL h−1 | NR | Kwak et al., |
| Human acute monocytic leukemia cells (THP-1) | PM | CD45 | NdFeB permanent magnet | NR | 106 cells mL−1 | NR | 4.2 mL h−1 | NR | Huang et al., |
| Human colon cancer cells (COLO205) | PM | EpCAM | Permanent magnet + nickel micromagnets | NR | ~60 cells mL−1 | Increased by 19% compared to no-micromagnet condition | 2.5 mL h−1 | NR | Chen et al., |
| Breast cancer cells (SKBR-3) | PM | EpCAM | NdFeB permanent magnet + ferromagnetic nickel-iron wires | 97% | 7 × 101-6 × 104 cells mL−1 | 90% | 2–5 mL h−1 | 100% of the isolated cells were intact | Kim et al., |
| Breast cancer cells (MCF-7) | PM | EpCAM | NdFeB permanent magnet + ferromagnetic nickel-cobalt wires | NR | 1.25−2.5 × 105 cells mL−1 | 93% | 2.4–6 mL h−1 | NR | Park et al., |
| Breast cancer cells (MCF-7) | PM | EpCAM | NdFeB permanent magnet + ferromagnetic nickel-iron wires | 6.9–67.9% | 1–10 cells mL−1 | 99.08% | 4 mL h−1 | NR | Cho et al., |
| Human lung cancer cells (A549) | PM | EpCAM | Permanent magnet + silicon wires | NR | 5 × 103 cells mL−1 | ~90% | ~1 mL h−1 | Re-collected cells showed almost the same morphology compared to control cells | Wang et al., |
| (i) Lung cancer cells | PM | ||||||||
| Human ovarian cancer cells (HeLa) | PM | EpCAM | Nickel-iron -based microstripline | NR | 106 cells mL−1 | 79% | 0.06 mL h−1 | 100% cell viability was obtained with cooling | Wong et al., |
| B lymphoid cells (Raji cell line) (target) | PM | CD19 | Cooled electromagnet coil + microcontact printed ferrofluidic dots | 96% | 2 × 106 cells mL−1 | 94% | 3.6 × 104 – | Viable cells with ability to move and divide were reported | Saliba et al., |
| Human lung cancer cells (A549) | PM | WGA modification | Magnetic solenoid coil + nickel micropillars | ~93% | 1.5 × 105 cells mL−1 | 62–74% | NR | NR | Liu et al., |
| Human T-lymphocytic | PM | CD4 | NdFeB permanent magnet | >90% | ~2 × 106 mL−1 | NR | ~3.6 × 105 cells h−1 | NR | Mizuno et al., |
| Breast cancer cells (MCF-7) | PM | EpCAM | NdFeB permanent magnets + | NR | 103−3.3 × 104 cells mL−1 | up to 88% | ~0.1 mL h−1 | NR | Kirby et al., |
| Lung carcinoma cells (H1299-GFP) | PM | CD45 | Permanent magnet | ~50% | 101-105 cells mL−1 | ~90% | 60 mL h−1 | >90% | Jiang et al., |
| Human ovarian cancer cells (HeLa) | PM | NU | NdFeB permanent magnet | NR | 5 × 105 cells mL−1 | NR | NR | NR | Pamme and Wilhelm, |
| Breast cancer cells | PM | NU | Permanent magnet +ferromagnetic nickel wire | NR | NR | 94.8% | 0.0025–0.0200 mL h−1 | NR | Han et al., |
| Breast cancer cells | PM | EpCAM | Quadrupole magnetic circuit | >3.5-log purification resulted in 1,500 WBCs mL−1 | 200–1,000 cells mL−1 | SKBR3: | 8 mL h−1 | Viable cells were obtained | Ozkumur et al., |
| Human breast cancer cells (MCF10A and MCF10A-LBX1) | PM | CD45 | 2.5-log purification resulted in 32,000 WBCs mL−1 | MCF10A: 96.7 ± 1.9% | |||||
| Human melanoma cells (WM164), breast cancer cells (MB231, SKBR3), human lung cancer cells (PC9) and prostate cancer cells (PC3-9) | PM | CD66b | Permanent magnet | 3.8-log purification | ~103 cells mL−1 | 97% | 8 mL h−1 | NR | Karabacak et al., |
| Human melanoma cells (SkMel28), lung cancer cells (H1650, H1975, H3122), prostate cancer cells (NCAP, PC3, PC3-9, VCAP) and breast cancer cells (MB231, MCF-7, SkBR) | PM | CD66b | Magnetic circuit | Purification resulted in 445 WBC mL−1 | 19–5,000 cells mL−1 | 99.5% | 5.4−7.2 × 1010 cells h−1 | NR | Fachin et al., |
| Human colon cancer cells (HCT8) | PM | CD45 | Permanent magnet | Purification resulted in | 104 cells mL−1 | 70 ± 5% | NR | Unchanged cell viability when a pulsation frequency of 0.05 Hz was used | Luo et al., |
| Colorectal adenocarcinoma cells (HT29) | PM | CD45 | Magnet + layer of NdFeB magnetic grains | NR | 50- 250 cells mL−1 | 87–96% | 5 mL h−1 | NR | Chung et al., |
| Oncogenic human monocyte cells (U937) | NM | NU | NdFeB permanent magnet + nickel microstructure | >90% | 8 × 107 cells mL−1 (U937: RBC = 1:400) | NR | 105 cells h−1 | NR | Shen et al., |
| Breast cancer cells (MDA-MB-231), colorectal cancer cells (HCT116 and HT29), lung cancer cells (HCC827) and esophageal cancer cells (JHEsoAD1) | NM | NU | NdFeB permanent magnet | NR | NR | NR | No flow | Unchanged cell viability for long term cultivation in paramagnetic medium was reported | Durmus et al., |
| Breast cancer cells (MDAMB-231), lung cancer cells (A549), ovarian | NM | NU | NdFeB permanent magnet | NR | NR | NR | 0.36 mL h−1 | NR | Amin et al., |
PM, positive magnetophoresis; NM, negative magnetophoresis.
NR, not reported; NU, not used.
Capture rate, the ratio of the number of cells collected after separation to the total number of cells loaded to the chip.
Purity, the ratio of the number of target cells collected after separation to the total number of collected cells.
Figure 2Microfluidic stem cell separation device. Magnetophoretic HSC and EPC separation based on anti-CD133-conjugated magnetic labeling. (i) Illustration and (ii) photograph of the device. (iii) Magnetic field created by electromagnetic wires deflects magnetically-labeled stem cells into a center collection stream. Reprinted with permission from Plouffe et al. (2012). Copyright (2012) American Chemical Society.
Figure 3Microfluidic tumor cell separation devices. (A) Separation of magnetically-labeled target cells. (i) Design and (ii) optical micrograph of the positive tumor cell (SKBR-3) enrichment device using anti-EpCAM-coupled magnetic nanoparticles. Reprinted with permission from Kim et al. (2013b). Copyright (2013) American Chemical Society. (B) In situ magnetic labeling of tumor cells (Ephesia). (i) The magnetic beads are located on ferrofluid dots in the microfluidic channel to create a self-assembled magnetic bead array under the applied magnetic field. (ii) Cells are captured on the magnetic bead array during the sample flow. Reprinted from Saliba et al. (2010). (C) Separation of tumor cells (HeLa) based on MNP uptake extent. (i) The schematic illustration of the device. (ii) HeLa cells are deflected from the laminar flow according to their magnetic load. Reprinted with permission from Pamme and Wilhelm (2006). Copyright (2006) The Royal Society of Chemistry. (D) Separation of cancer cells by depleting other cells. (i) A monolithic microfluidic chip for negative enrichment of tumor cells through the depletion of magnetically-labeled WBCs. In the deterministic lateral displacement (DLD) part, RBCs, platelets, and free beads are eliminated. Following the inertial focusing 1 (IF1), magnetophoresis (MACS1) is applied to deplete magnetic labeled WBCs having more than ~6 beads. Another set of inertial focusing (IF2) and magnetophoresis (MACS2) is applied to deplete WBCs that contain at least one magnetic bead. (ii) Image of cell streaks captured using fluorescence microscopy on different areas of the chip. Green and yellow colors represent WBCs and CTCs, respectively. Reprinted from Fachin et al. (2017). (E) Tumor cell separation using cells' intrinsic properties in a paramagnetic solution. (i) The design of the label-free magnetophoresis platform (MagLev). (ii) Alignment of tumor cells at different heights (z-axis) in the device. Reprinted from Durmus et al. (2015).
Figure 4Magnetic force-based 2D and 3D cell culture techniques. (I) Formation of 3D cellular assembly as building blocks, (II) Organizing cells or spheroids into a targeted pattern, (III) Guiding cells into sheet-like structures for a close cellular contact, and (IV) Enhancing the seeding efficiency of the cells into scaffolds.
Summary of 3D cellular assembly applications.
| PM (labeling cells via internalization using bovine serum albumin coated MNP) | Human prostate cancer epithelial (PC-3) cells and human lung fibroblast (HFL-1) cells | Multilayer sheet structures for epithelial cells, tightly packed spheroids for fibroblasts after 24 h of manipulation. | - | Ghosh et al., |
| PM (labeling cells via a hydrogel consisting of gold, iron oxide MNP and filamentous bacteriophage) | Normal human astrocytes and human glioblastoma (LN-229 or U-251MG) | Spheroids with ~ 930 μm diameter after 10.5 days of levitation | - | Souza et al., |
| PM (labeling cells via NANOSHUTTLE™) | Preadipocyte cells (3T3-L1) and endothelial cells (bEND.3) | Adiposphere-based coculture with a vascular-like network assembly and lipogenesis in perivascular cells. | - | Daquinag et al., |
| PM (labeling cells via NANOSHUTTLE™) | Primary human epithelial cells, smooth muscle cells, pulmonary fibroblasts, and pulmonary endothelial cells | 3D bronchiole coculture consisting of four cell types together in a layered assembly after 7 days of levitation culture | - | Tseng et al., |
| PM (labeling cells via NANOSHUTTLE™) | Primary porcine valvular interstitial cells and endothelial cells | 3D layered co-culture model of the aortic valve with ~ 2800 μm diameter after 3 days of levitation | - | Tseng et al., |
| PM (labeling cells via NANOSHUTTLE™) | Breast cancer cells (SUM159, MDA-MB-231) and fibroblasts (293T, Hs578bst, human pulmonary fibroblasts and patient derived tumor associated fibroblasts) | Large-sized (millimeter in diameter) co-culture model of breast tumor within 24 h | - | Jaganathan et al., |
| PM (labeling cells via MNP) | Bone marrow-derived human MSCs | Random mixed, core-shell, and fused spheroids composed of cells stained with two different dyes with 100–200 μm in diameter | - | Kim et al., |
| PM (labeling cells via NANOSHUTTLE™) | Rat vascular smooth muscle cells (A10) and primary human aortic smooth muscle cells | Contractile rings with ~ 3 mm in outer diameter | - | Tseng et al., |
| PM (labeling cells via magnetite cationic liposomes) | Mouse myoblast cells (C2C12) | Cell sheets with 0.63 cm2 area after 24 h, cell strings with ~150 μm in longitudinal direction after 24 h, cell rings with 12 mm in diameter after 48 h | - | Yamamoto et al., |
| PM (labeling cells via magnetite cationic liposomes) | Primary neonatal rat cardiomyocytes | Cardiac tissue rings with ~250 μm thickness after 7-day cultivation | - | Akiyama et al., |
| PM (labeling 3D cellular spheroids via incorporation of magnetoferritin nanoparticles into spheroids) | Primary rat aortic smooth muscle cells | Tissue rings formed by fusion of spheroids over 4 days (~ 13 mm in diameter) | - | Mattix et al., |
| PM (labeling 3D cellular spheroids via incorporation of MNP into ECM of spheroids) | Primary rat aortic smooth muscle cells | Tissue rings (from 2 mm up to 10 mm) and custom patterns (square and Clemson University Tiger Paw) formed by fusion of magnetic labeled spheroids over 4 days | - | Mattix et al., |
| PM (labeling cells via deposition of poly(allylamine)-stabilized MNP on cell membranes) | Primary human skin fibroblasts (HSF) and human lung carcinoma epithelial cells (A549) | Layered planar tissue constructs (~100 μm thick, round, and 3 mm in diameter) after 24 h incubation of surface-engineered magnetic cells | - | Dzamukova et al., |
| PM (forming magnetic 3D cellular structures via adhesion of cells to magnetic iron oxide-encapsulated nano/microparticle substrates) | Human epidermoid tumor KB cells | Tumor cell spheroids with an increase in volume during 10-day culture period | - | Lee et al., |
| PM (forming magnetic 3D cellular structures via adhesion of cells to magnetic collagen hydrogel beads) | Mouse fibroblast cells (NIH-3T3) and human hepatocellular carcinoma cells (Hep G2) | Magnetically manipulable cells adhered on the collagen beads | - | Sugaya et al., |
| PM (labeling biotinylated cells via streptavidin paramagnetic particles) | Human embryonic kidney cells (HEK293) and human breast cancer cells (MCF-7) | Magnetically orientable cells and spheroids in hanging drop culture to target and immobilize spheroids for a facilitated media change and therapeutic screening, covering different cells onto preformed spheroids | - | Ho et al., |
| NM (suspension of cells in paramagnetic solution containing gadolinium diethylenetriaminepentaacetic acid) | Bovine carotid artery cells (HH) | Egg-shaped cellular structure with 510 μm diameter and 690 μm height in 20 min | - | Akiyama and Morishima, |
| NM (suspension of cells in paramagnetic solution containing gadoteric acid) | Bovine carotid artery cells (HH) | Spheroids with ~400 μm in diameter after one day of culture (25 spheroids in each batch) | - | Akiyama and Morishima, |
| NM (suspension of cells in paramagnetic solution containing gadoteric acid) | Mouse myoblast cells (C2C12) | Spheroids with ~250 μm diameter within 1 min | + | Akiyama and Morishima, |
| NM (suspension of cells in paramagnetic solution containing gadolinium diethylenetriaminepentaacetic acid) | Whole blood cells | Rectangular bar, three-pointed star shaped cellular structures and spheroids of varying sizes (600–1,000 μm) | - | Abdel Fattah et al., |
| NM (suspension of cells in paramagnetic solution containing Gadavist®) | Murine fibroblasts (NIH 3T3) | Cellular clusters (100–260 μm) formed by magnetic levitation after 48 h, merged preformed-spheroids after 4 days and assembly of cells compartmentalized in the water-in-oil droplets after 24 h | + | Tocchio et al., |
| NM (suspension of spheroids in paramagnetic solution containing Omniscan™) | Primary sheep chondrocytes | Fused chondrospheres | - | Parfenov et al., |
| NM (suspension of cells in paramagnetic solution containing Gadavist®) | Bone marrow stem cells (D1 ORL UVA) and breast cancer cells (MDA-MB-231) | Cellular blocks up to ~2.7 cm in length (with ~280 μm thickness) formed by magnetic levitation after 48 h and biphasic cellular structures in a single device | + | Anil-Inevi et al., |
| NM (suspension of cells in paramagnetic solution containing Gadavist®) | Mouse fibroblast cells (NIH 3T3) and non-small-cell lung cancer cells (HCC827) | Cell spheroids and cell strings with increase in cell number during 168-h culture | + | Türker et al., |
| PM (forming magnetic 3D cellular structures via encapsulation of cell within paramagnetic hydrogel) | Mouse fibroblast cells (NIH 3T3) | Magnetically controllable cell-encapsulating hydrogels with manufacturability in different sizes (150 μm in thickness and 200–1,000 μm in side dimension) | - | Tasoglu et al., |
| NM (suspension of cells in paramagnetic solution containing gadolinium diethylenetriaminepentaacetic acid) | Mouse fibroblast cells (NIH 3T3) | Assembled building blocks; cell encapsulating hydrogels (2 mm round with 150 μm thickness) and cell seeded microbeads | - | Tasoglu et al., |
| PM (manipulation of cell encapsulating hydrogels via motion of the magnetic microrobots) | Human umbilical vein endothelial cells (HUVECs), mouse fibroblast cells (NIH 3T3), cardiomyocyte | 2D and 3D heterogeneous assembly of cell encapsulating hydrogels. | - | Tasoglu et al., |
PM, positive magnetophoresis; NM, negative magnetophoresis; MNP, magnetic nanoparticles; NANOSHUTTLE™, assembly of iron oxide and gold nanoparticles cross-linked with poly-l-lysine.
–, The shortest dimension of the cell culture chamber > 1 mm.
+, The shortest dimension of the cell culture chamber ≤ 1 mm.
Figure 5Magnetic force-based manipulation of magnetically labeled cells (positive magnetophoresis) and label-free diamagnetic cells (negative magnetophoresis). 3D assembly of magnetically labeled cells into a spheroid by a magnet (A) under the culture chamber, (B) on the top of the culture chamber and (C) by a magnetized pin beneath the magnet to concentrate the magnetic field for attracting cells in a focused direction. 3D assembly of magnetically labeled cells into a ring-shaped structure (D) using a cylindrical plug and a magnet under it to accumulate contractile cells around the plug and (E) using a ring-shaped magnet. 3D assembly of label-free diamagnetic cells into (F,G) spheroid, (H) three-pointed star and (I) rectangular bar in a magnetic liquid with different configurations of magnets to produce a spatially varying field along the culture chamber (The north poles: red, the south poles: blue).
Figure 6Levitation of diamagnetic cells with negative magnetophoresis; patterning of pre-formed spheroids into the tissue strings and in situ 3D cellular assembly. (A) Serial coding of spatially controlled spheroids. Spheroids were formed separately and then inserted into the levitation device (spheroids; R, red; G, green; B, blue) Scale bars, 100 μm. Reprinted from Tocchio et al. (2017). Copyright (2017) John Wiley & Sons, Inc. (B) Cellular assembly of D1 ORL UVAeGFP and MDA-MB-231dsRed cells under microgravity. Confocal and conventional fluorescence microscopy (upper left) images showing self-assembled coculture clusters formed with magnetic levitation (100 mM Gd-BT-DO3A) and different cell loading strategies; L1: simultaneously loading of MDA-MB-231dsRed and D1 ORL UVAeGFP cells, L2: MDA-MB-231dsRed cells onto D1 ORL UVAeGFP clusters formed with magnetic levitation and L3: D1 ORL UVAeGFP cells onto MDA-MB-231dsRed clusters formed with magnetic levitation (total 50,000 cells/culture chamber). Scale bars: 200 μm. Reprinted from Anil-Inevi et al. (2018).
Biocompatibility of magnetic liquids.
| Gadolinium diethylenetriaminepentaacetic acid | Linear ionic | NR | + | Winkleman et al., |
| ++ | NR | Rodríguez-Villarreal et al., | ||
| ++++ | NR | Abdel Fattah et al., | ||
| Gadoteridol | Macrocyclic nonionic | NR | +++ | Kauffmann et al., |
| Gadabutrol (Gadavist®) | Macrocyclic nonionic | NR | ++++ | Durmus et al., |
| NR | +++ | Tocchio et al., | ||
| Gadodiamide (Omniscan™) | Linear nonionic | NR | ++ | Anil-Inevi et al., |
| Gadopentetate dimeglumine (Magnevist®) | Linear ionic | NR | +++ | Anil-Inevi et al., |
| Gadoterate meglumine (Dotarem®) | Macrocyclic ionic | NR | ++ | Kauffmann et al., |
| NR | +++ | Anil-Inevi et al., | ||
| Gadobenate dimeglumine (Multihance®) | Linear ionic | NR | ± | Kauffmann et al., |
| NR | +++ | Anil-Inevi et al., | ||
| BSA (bovine serum albumin) coated ferrofluid | Globular protein-magnetite nanoparticles | ± | NR | Krebs et al., |
| Citrate stabilized ferrofluid | Citrate anion-Cobalt-ferrite nanoparticles | – | NR | Kose et al., |
| EMG 408 ferrofluid | Anionic surfactant- magnetite nanoparticles | ++++ | NR | Zhu et al., |
| Graft copolymer functionalized ferrofluid | Nonionic polymers-maghemite nanoparticles | ++++ ++++ | NR | Zhao et al., |
| ++ | NR | Zhao et al., |
Cell viability which was not statistically different from the control group, or above 80% was assessed as good cell viability. Good cell viability levels were scored as– (< 10 mM), ± (10–25 mM), + (25–50 mM), ++ (50–100 mM), +++ (100–200 mM) or ++++ (>200 mM) for paramagnetic salt solutions. Good cell viability in ferrofluids were scored as– (good cell viability: < 0.06%, volume fraction of magnetic particles), ± (0.06–0.12%), + (0.12–0.25%), ++ (0.25–0.5%), +++ (0.5–1%) or ++++ (>1%). NR stands for “not reported,” respectively.